From Sven: “As the founder of an early stage company, I’ve participated in a number of early stage accelerators and the VCIC experience stood out in providing the most ‘value per time invested’. I walked away from a (fun!) weekend much better equipped to confidently and clearly communicate my value prop to investors. Furthermore, it’s a unique opportunity for founders to network with investors in a casual environment and form meaningful connections over an entire weekend.”
Platelet Biogenesis Raises $10M Series A Eight Weeks After VCIC.
Platelet BioGenesis is a Harvard University spinout that is making human platelets from stem cells. We have developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human pluripotent stem cell cultures. By removing the volunteer donor, we can make platelets that are cheaper, safer, and available on demand.